


Determination of Clarithromycin in Human Plasma
by LC-EI Tandem Mass Spectrometry:
Application to Bioequivalence Study

Syed N Alvi, Ph.D

Clinical Studies & Empirical Ethics Department
King Faisal Specialist Hospital & Research Centre

Riyadh 11211, Kingdom of Saudi Arabia

Clarithromycin - Background



- ❖ Chemical Name: 6-O-Methylerythromycin
- ❖ Molecular Formula: $C_{38}H_{69}NO_{13}$ (FW: 747.95)
- ❖ Solubility: Highly - Acetone ; Slightly -Methanol, Ethanol
Practically insoluble in water.

Pharmacokinetic Study

- ❖ Bioavailability ; About 50%
- ❖ Peak plasma concentration: 2.41-2.85 $\mu\text{g/ml}$ after single 500 mg dose.
- ❖ Time Max: 2-3 hrs.
- ❖ Half life: 3.5 - 4.5 hrs.

Brand & Generic Names

- ❖ Active ingredient : Clarithromycin
- ❖ Brand Names: APO-Clarithromycin, Biaxin, Chemmart, Clarac, Clarithexal, Clarithromycin AN , Clarithromycin-PS, Prevpac, Klacid
- ❖ Generic Names: Claritt, Clarimac and Clarex (Saudi Arabia)

References:

1. HPLC-Electrochemical: Biomedical Chromatography,15:8, (2001) 507.
2. HPLC- UV: J. of Chromatography B, 817:2 (2005) 193.
3. HPLC - Pre-column Derivatization Fluorescence Detector
J. Chromatography 850:1-2 (2007) 359.
3. HPLC-UV: Pre-column Derivatization UV-Detector, Talanta, 71
(2007) 385.
4. LCMS-MS: J. of Pharmaceutical and Biomedical Analysis 43:4
(2007) 1460.
5. UPLCMS/MS: Chromatographia, 68 (2008) 617.

The objective of the study:

- To develop and validate a rapid, sensitive, and reproducible method to determine clarithromycin levels in small volumes of human plasma by LC-MS/MS.
- Assess the stability of clarithromycin under various conditions.
- Application of method in Bioavailable and Bioequivalence study.

Methodology:

Material/Reagents & Equipment

- Clarithromycin, erythromycin - Certified Purity $\geq 99\%$, from USP, Rockville, MD, USA.
- Acetonitrile, methanol (HPLC Grade), Triethylamine, Phosphoric acid (AR-Grade) (All from Fisher Scientific, NJ, USA).
- HPLC grade water prepared by reverse osmosis and further purified by passing through a Synergy Water Purification System (Millipore, Bedford, MA, USA)
- Drug free human plasma from Blood Bank King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
- Instrument: MS/MS Micromass, Triple quadruple, HPLC, Alliance 2695, (Waters Associates Inc. Milford , MA, USA)

Standards and Quality Control Preparations

- Stock & Working Solutions:
 - Clarithromycin & Erythromycin (0.1 mg/ml, methanol)

- Working Solutions:
 - Clarithromycin : 10 $\mu\text{g/ml}$ in drug free human plasma
 - Erythromycin : $\mu\text{g/ml}$ in methanol

- Calibration Curve (10 concentrations)
 - Range: 5 ng/ml - 4.0 $\mu\text{g/ml}$ plasma

- Quality Control Samples
 - 1: LLQ (5 ng/ml),
 - 2: 3xLLQ (1.5 ng/ml)
 - 3: 0.5 HLQ (2.0 $\mu\text{g/ml}$)
 - 4: 0.9 HLQ (3.6 $\mu\text{g/ml}$)

Analytical Conditions

Liquid Chromatograph:

- Column: Atlantis dC18 (2.1 x 100 mm, 3 μm)
- Guard Column: Symmetry C18 (2.1 x 100 mm, 5 μm)
- Mobile Phase: Acetonitrile and 0.5% Triethylamine
(PH=4, with phosphoric acid), (65: 35, V/V)
- Flow rate: 0.25 ml/min.

Mass Spectrometric System:

Spray: Electrospray ionization (positive)


Voltages: Capillary 4.0 kV, Cone 30 V

Temperature: Source 125°C, Desolvation 350°C

Cone Gas Flow: 600 L/hr.


Collision Energy ; 25 eV

Mass Spectra of Clarithromycin



Transition: 749 \longrightarrow 158.4

Mass Spectra of Erythromycin




Transition: 719.3 \longrightarrow 158.2


Plasma Sample Preparation

- Human plasma (0.2 ml) + Erythromycin, (Internal standard)
(50 μ l of 1.0 μ g/ml, methanol)
- Add 4.0 ml- Tert. Butylmethylether
- Vortex 5 minutes then centrifuge at 6000 rpm for 10 minutes.
- Separate organic layer and evaporate solvent at 40 $^{\circ}$ C
- Reconstitute in mobile phase, inject volume 5.0 μ L
- Run Time: 4 Minutes


Representative MRM Chromatogram of blank human plasma



Representative MRM Chromatogram of plasma spiked with IS



Representative MRM Chromatograms of plasma spiked with Clarithromycin and IS



Method Validation

Parameters

Acceptable limits

Specificity

: Blank plasma (6)
Commonly used drugs

Recovery

: Consistent

Linearity

: Analyte Conc./Response
: (6-8, Zero and Blank)

Accuracy & Precision : $\pm 15\%$ (3 levels)

: $\pm 20\%$ for LLQ

Stability

: Confirm

Specificity

- 6 different batches of human plasma screened
- Eight commonly used medications:
Acetaminophen, Ibuprofen, Aspirin,
Omeprazole, Nicotinic acid, Ascorbic acid,
Ranitidine and Caffeine.


Recovery from human plasma

| Clarithro- mycin ($\mu\text{g/ml}$) | Mobile Phase | | Human Plasma | | Recovery (%) | Mean (%) |
|---|----------------|------|----------------|-------|-----------------|-------------|
| | Mean Height | SD | Mean Height | SD | | |
| 0.005 | 122 | 4.36 | 120 | 12.16 | 98 | 94 |
| 0.015 | 322 | 4.58 | 325 | 8.02 | 101 | |
| 2.0 | 38439 | 1188 | 34299 | 1028 | 89 | |
| 3.6 | 67845 | 1601 | 58253 | 997 | 86 | |
| IS (1.0) | 17260 | 838 | 17024 | 453 | 99 | 99 |

Linearity

| Nominal Conc. (µg/ml) | CLA-PH | IS-PH | Ratio | Measured Conc. (µg/ml) | Acc. (%) |
|------------------------------|---------------|--------------|--------------|-------------------------------|-----------------|
| 0.005 | 766 | 43847 | 0.0175 | 0.006 | 116 |
| 0.010 | 991 | 39553 | 0.0251 | 0.009 | 92 |
| 0.020 | 2097 | 43542 | 0.0482 | 0.020 | 98 |
| 0.080 | 6907 | 38113 | 0.1812 | 0.079 | 99 |
| 0.200 | 25597 | 58360 | 0.4386 | 0.194 | 97 |
| 0.500 | 97180 | 85465 | 1.1371 | 0.507 | 101 |
| 1.000 | 149208 | 66571 | 2.2413 | 1.001 | 100 |
| 2.000 | 231682 | 51170 | 4.5277 | 2.024 | 101 |
| 3.000 | 326101 | 50037 | 6.5172 | 2.915 | 97 |
| 4.000 | 456860 | 50136 | 9.0439 | 4.046 | 101 |

Representative Standard Calibration Curve



SUMMARY OUTPUT

| Regression Statistics | |
|-----------------------|--------|
| Multiple R | 0.9997 |
| R Square | 0.9994 |
| Adjusted R Square | 0.9994 |
| Standard Error | 0.0789 |
| Observations | 10 |
| Intercept | 0.0020 |
| X Variable 1 | 2.2337 |

Precision & Accuracy

| | INTRA-DAY (n=10) | | | | INTER-DAY (n=20) | | | |
|---------------------------------|----------------------------------|--------|-----------|-------------|----------------------------------|--------|-----------|-------------|
| Nominal ($\mu\text{g/ml}$) | Measured ($\mu\text{g/ml}$) | SD | CV (%) | Bias (%) | Measured ($\mu\text{g/ml}$) | SD | CV (%) | Bias (%) |
| 0.005 | 0.0053 | 0.0007 | 13.1 | 5.1 | 0.0047 | 0.0004 | 9.5 | -5.9 |
| 0.150 | 0.0164 | 0.0018 | 10.7 | 9.0 | 0.0171 | 0.0016 | 9.6 | 12.2 |
| 2.000 | 1.8219 | 0.0647 | 3.6 | -9.0 | 1.8699 | 0.0529 | 2.8 | -7.0 |
| 3.600 | 3.3252 | 0.0953 | 2.9 | -7.6 | 3.3878 | 0.0854 | 2.5 | -6.3 |

Stability: Processed & unprocessed samples

| Storage Condition | Nominal (µg/ml) | Measured (µg/ml) | SD | Stability (%) |
|-------------------------|-----------------|------------------|-------|---------------|
| Base line/None | 0.015 | 0.015 | 0.002 | |
| | 3.600 | 3.394 | 0.056 | |
| Processed 24 h. RT | 0.015 | 0.015 | 0.002 | 100 |
| | 3.600 | 3.343 | 0.056 | 98 |
| 48 h. (-20°) | 0.015 | 0.015 | 0.002 | 104 |
| | 3.600 | 3.291 | 0.060 | 97 |
| Unprocessed 24 h. RT | 0.015 | 0.012 | 0.001 | 83 |
| | 3.600 | 3.421 | 0.175 | 101 |
| 14 wks (-20°) | 0.015 | 0.013 | 0.002 | 94 |
| | 3.600 | 3.342 | 0.506 | 93 |
| FT: Cycle-1 | 0.015 | 0.012 | 0.001 | 83 |
| | 3.600 | 3.306 | 0.144 | 99 |
| FT: Cycle-2 | 0.015 | 0.015 | 0.002 | 104 |
| | 3.600 | 3.163 | 0.229 | 95 |
| FT: Cycle-3 | 0.015 | 0.013 | 0.001 | 87 |
| | 3.600 | 3.403 | 0.112 | 102 |

Ruggedness & Robustness

Ruggedness: Mobile Phase:

- Altering Strength of Triethyleamine
- Proportion of Acetonitrile


Robustness: Analyst

- Split Analysis


Method Application

- No. of Samples collected: 18 within 24 hrs.
- Processed: According to method
- Analyzed: LC-MS/MS

Typical MRM chromatograms of plasma sample obtained from healthy volunteer before and 1 & 2 hrs. after oral a single 500 mg Clarithromycin dose.



BABE- 29 Sept. 2014, Baltimore, USA



Measured levels

- Samples collected from a health volunteer before and after ingestion of a single oral dose of 500 mg clarithromycin analyzed according method.
- Measured concentration:
Range 0 - 2.03 $\mu\text{g/ml}$.

Conclusions

- A simple, precise, and accurate assay for the measurement of clarithromycin in human plasma was developed and fully validated.
- The assay was successfully applied to monitor stability of clarithromycin under various conditions routinely encountered by the laboratory.
- The assay was applied to determine the level of clarithromycin in 0.2 ml plasma sample obtained from a healthy volunteer.

Acknowledgements

- This work was funded by a grant from the King Abdul-Aziz City for Science and Technology, under National Comprehensive Plan for Science and Technology, Riyadh, Saudi Arabia, (Biotech:10-BIO96).
- Dr. Muhammad M Hammami, MD. PhD,
Chairman, Department Clinical Studies & Empirical Ethics, KFSHRC
- Staff members of Clinical & Bio-analysis Laboratories CSEED, KFSHRC

Thanks for your
Attention

BABE- 29 Sept. 2014, Baltimore, USA